Below are the most recent publications written about "Atrial Flutter" by people in Profiles.
-
Jain SS, Mahaffey KW, Pieper KS, Shimizu W, Potpara T, Ruff CT, Kamel H, Lewis BS, Cornel JH, Kowey PR, Horrow J, Strony J, Plotnikov AN, Li D, Weng S, Donahue J, Gibson CM, Steg PG, Mehran R, Weitz JI, Johnston SC, Hankey GJ, Harrington RA, Lam CSP. Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design. Am Heart J. 2024 Nov; 277:145-158.
-
Raisi-Estabragh Z, Kobo O, Elbadawi A, Velagapudi P, Sharma G, Bullock-Palmer RP, Petersen SE, Mehta LS, Ullah W, Roguin A, Sun LY, Mamas MA. Differential Patterns and Outcomes of 20.6?Million Cardiovascular Emergency Department Encounters for Men and Women in the United States. J Am Heart Assoc. 2022 10 04; 11(19):e026432.
-
Crijns HJGM, Elvan A, Al-Windy N, Tuininga YS, Badings E, Aksoy I, Van Gelder IC, Madhavapeddi P, Camm AJ, Kowey PR, Ruskin JN, Belardinelli L. Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm. Circ Arrhythm Electrophysiol. 2022 03; 15(3):e010204.
-
Sacchetti A, Wisdom D, Hennessey A, Simcoe R. Patient history alone identifies candidates safe for cardioversion of recent onset atrial fibrillation or flutter. Am J Emerg Med. 2022 07; 57:217.
-
Thind M, McKindley DS, Reiffel JA, Naccarelli GV, Stewart J, Kowey PR. Predictors of dronedarone plasma drug concentrations and effect on atrial fibrillation/atrial flutter recurrence: Analyses from the EURIDIS and ADONIS studies. Clin Cardiol. 2022 Jan; 45(1):119-128.
-
Thind M, Zareba W, Atar D, Crijns HJGM, Zhu J, Pak HN, Reiffel J, Ludwigs U, Wieloch M, Stewart J, Kowey P. Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS-ADONIS trials. Clin Cardiol. 2022 Jan; 45(1):101-109.
-
Naccarelli GV, Filippone EJ, Foy A. Do Mineralocorticoid Receptor Antagonists Suppress Atrial?Fibrillation/Flutter? J Am Coll Cardiol. 2021 07 13; 78(2):153-155.
-
Thind M, Crijns HJ, Naccarelli GV, Reiffel JA, Corp Dit Genti V, Wieloch M, Koren A, Kowey PR. Dronedarone treatment following cardioversion in patients with atrial fibrillation/flutter: A post hoc analysis of the EURIDIS and ADONIS trials. J Cardiovasc Electrophysiol. 2020 05; 31(5):1022-1030.
-
Vamos M, Calkins H, Kowey PR, Torp-Pedersen CT, Corp Dit Genti V, Wieloch M, Koren A, Hohnloser SH. Efficacy and safety of dronedarone in patients with a prior ablation for atrial fibrillation/flutter: Insights from the ATHENA study. Clin Cardiol. 2020 Mar; 43(3):291-297.
-
Ueberham L, K?nig S, Hohenstein S, Mueller-Roething R, Wiedemann M, Schade A, Seyfarth M, Sause A, Neuser H, Staudt A, Zacharzowsky U, Reithmann C, Shin DI, Andrie R, Wetzel U, Tebbenjohanns J, Wunderlich C, Kuhlen R, Hindricks G, Bollmann A. Sex differences of resource utilisation and outcomes in patients with atrial arrhythmias and heart failure. Heart. 2020 04; 106(7):527-533.